Cellular Plasticity in Cancer
- PMID: 30992279
- PMCID: PMC6606363
- DOI: 10.1158/2159-8290.CD-19-0015
Cellular Plasticity in Cancer
Abstract
During cancer progression, tumor cells undergo molecular and phenotypic changes collectively referred to as cellular plasticity. Such changes result from microenvironmental cues, stochastic genetic and epigenetic alterations, and/or treatment-imposed selective pressures, thereby contributing to tumor heterogeneity and therapy resistance. Epithelial-mesenchymal plasticity is the best-known case of tumor cell plasticity, but recent work has uncovered other examples, often with functional consequences. In this review, we explore the nature and role(s) of these diverse cellular plasticity programs in premalignant progression, tumor evolution, and adaptation to therapy and consider ways in which targeting plasticity could lead to novel anticancer treatments. SIGNIFICANCE: Changes in cell identity, or cellular plasticity, are common at different stages of tumor progression, and it has become clear that cellular plasticity can be a potent mediator of tumor progression and chemoresistance. Understanding the mechanisms underlying the various forms of cell plasticity may deliver new strategies for targeting the most lethal aspects of cancer: metastasis and resistance to therapy.
©2019 American Association for Cancer Research.
Conflict of interest statement
Disclosure of Potential Conflicts of Interests
The authors declare no potential conflicts of interest.
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6606363/bin/nihms-1523817-f0001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6606363/bin/nihms-1523817-f0002.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6606363/bin/nihms-1523817-f0003.gif)
![Figure 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6606363/bin/nihms-1523817-f0004.gif)
Similar articles
-
Dynamic interplay of nuclear receptors in tumor cell plasticity and drug resistance: Shifting gears in malignant transformations and applications in cancer therapeutics.Cancer Metastasis Rev. 2024 Mar;43(1):321-362. doi: 10.1007/s10555-024-10171-0. Epub 2024 Mar 22. Cancer Metastasis Rev. 2024. PMID: 38517618 Review.
-
Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis.Dev Cell. 2019 May 6;49(3):361-374. doi: 10.1016/j.devcel.2019.04.010. Dev Cell. 2019. PMID: 31063755 Free PMC article. Review.
-
Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance.Cell Stem Cell. 2019 Jan 3;24(1):65-78. doi: 10.1016/j.stem.2018.11.011. Epub 2018 Dec 13. Cell Stem Cell. 2019. PMID: 30554963 Free PMC article. Review.
-
Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer.Theranostics. 2020 May 15;10(14):6261-6277. doi: 10.7150/thno.42523. eCollection 2020. Theranostics. 2020. PMID: 32483452 Free PMC article. Review.
-
Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance.Cancer Metastasis Rev. 2024 Mar;43(1):197-228. doi: 10.1007/s10555-024-10172-z. Epub 2024 Feb 8. Cancer Metastasis Rev. 2024. PMID: 38329598 Free PMC article. Review.
Cited by
-
Co-Delivery of an Innovative Organoselenium Compound and Paclitaxel by pH-Responsive PCL Nanoparticles to Synergistically Overcome Multidrug Resistance in Cancer.Pharmaceutics. 2024 Apr 26;16(5):590. doi: 10.3390/pharmaceutics16050590. Pharmaceutics. 2024. PMID: 38794252 Free PMC article.
-
The roles of PD-L1 in the various stages of tumor metastasis.Cancer Metastasis Rev. 2024 May 11. doi: 10.1007/s10555-024-10189-4. Online ahead of print. Cancer Metastasis Rev. 2024. PMID: 38733457 Review.
-
Plasticity in cell migration modes across development, physiology, and disease.Front Cell Dev Biol. 2024 Apr 23;12:1363361. doi: 10.3389/fcell.2024.1363361. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38715921 Free PMC article. Review.
-
Statins as anti-tumor agents: A paradigm for repurposed drugs.Cancer Rep (Hoboken). 2024 May;7(5):e2078. doi: 10.1002/cnr2.2078. Cancer Rep (Hoboken). 2024. PMID: 38711272 Free PMC article. Review.
-
Iron metabolism: backfire of cancer cell stemness and therapeutic modalities.Cancer Cell Int. 2024 May 4;24(1):157. doi: 10.1186/s12935-024-03329-x. Cancer Cell Int. 2024. PMID: 38704599 Free PMC article. Review.
References
-
- Spechler SJ, and Souza RF (2014). Barrett’s esophagus. The New England journal of medicine 371, 836–845. - PubMed
-
- Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, and Funch-Jensen P (2011). Incidence of adenocarcinoma among patients with Barrett’s esophagus. The New England journal of medicine 365, 1375–1383. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases